<DOC>
	<DOCNO>NCT00898833</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood urine patient cancer laboratory may help doctor identify learn biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This laboratory study measure plasma urine biomarkers patient advanced prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Plasma Urine Samples From Patients With Hormone-Refractory Prostate Cancer Enrolled Clinical Trials CALGB-9480 CALGB-9583</brief_title>
	<detailed_description>OBJECTIVES : Primary - Correlate plasma urine vascular endothelial growth factor ( VEGF ) level survival duration patient advance hormone-refractory adenocarcinoma prostate previously enrol CALGB-9480 . - Determine whether plasma chromogranin A ( CgA ) plasma interleukin-6 ( IL-6 ) level predict survival duration patient . - Determine whether plasma human Kallikrein 2 ( hK2 ) level prognostic overall survival patient . Secondary - Determine prognostic significance plasma urine VEGF level , plasma CgA level , plasma IL-6 level , plasma hK2 level relation overall survival patient . - Correlate plasma VEGF level urine VEGF level patient . - Correlate plasma CgA level previously measure serum prostate-specific antigen ( PSA ) plasma VEGF level patient . - Correlate plasma hK2 level PSA change treatment suramin determine hK2 may predictive value , independent additive measure disease response patient . - Correlate plasma hK2 level PSA level patient . OUTLINE : Plasma patient collect measurement follow biomarkers : vascular endothelial growth factor ( VEGF ) , chromogranin A , interleukin-6 , human Kallikrein 2 . Urine collect VEGF measurement .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Registration CALGB 9480 9583 Samples collect ship appropriately Institutional Review Board ( IRB ) review approval institution laboratory work perform require</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>adenocarcinoma prostate</keyword>
</DOC>